Žilovič Diana, Čiurlienė Rūta, Sabaliauskaitė Rasa, Jarmalaitė Sonata
Life Sciences Center, Institute of Biosciences, Vilnius University, Saulėtekio Avenue 7, LT-10222 Vilnius, Lithuania.
Laboratory of Clinical Oncology, National Cancer Institute, Santariškių 1, LT-08406 Vilnius, Lithuania.
Cancers (Basel). 2021 Jul 30;13(15):3840. doi: 10.3390/cancers13153840.
Current diagnostic tools used in clinical practice such as transvaginal ultrasound, CA 125, and HE4 are not sensitive and specific enough to diagnose OC in the early stages. A lack of early symptoms and an effective asymptomatic population screening strategy leads to a poor prognosis in OC. New diagnostic and screening methods are urgently needed for early OC diagnosis. Liquid biopsies have been considered as a new noninvasive and promising method, using plasma/serum, uterine lavage, and urine samples for early cancer detection. We analyzed recent studies on molecular biomarkers with specific emphasis on liquid biopsy methods and diagnostic efficacy for OC through the detection of circulating tumor cells, circulating cell-free DNA, small noncoding RNAs, and tumor-educated platelets.
目前临床实践中使用的诊断工具，如经阴道超声、CA 125和HE4，在早期诊断卵巢癌（OC）时不够敏感和特异。缺乏早期症状以及有效的无症状人群筛查策略导致OC的预后较差。迫切需要新的诊断和筛查方法用于OC的早期诊断。液体活检被认为是一种新的非侵入性且有前景的方法，可使用血浆/血清、子宫灌洗和尿液样本进行早期癌症检测。我们分析了近期关于分子生物标志物的研究，特别强调了液体活检方法以及通过检测循环肿瘤细胞、循环游离DNA、小非编码RNA和肿瘤衍生血小板对OC的诊断效能。
